Further analysis of the CCL5/Sp1/CD44 axis in EpCAM+ cells revealed that this signaling pathway was more activated in advanced tumor stages, which was consistent with the protein analysis (Fig. 6J). This evidence concerns the gene CD44 and neoplasm.